Affordable Access

deepdyve-link
Publisher Website

The fate of urological systematic reviews registered in PROSPERO.

Authors
  • Khaleel, Sari1, 2
  • Cleveland, Brent1, 2
  • Kalapara, Arveen1, 3
  • Sathianathen, Niranjan1, 3
  • Balaji, Priyamvadha1
  • Dahm, Philipp4, 5
  • 1 Department of Urology, University of Minnesota, Minneapolis, MN, USA.
  • 2 Urology Section 112D, Minneapolis VA Medical Center, One Veterans Drive, Minneapolis, MN, 55417, USA.
  • 3 Peter MacCallum Cancer Institute, Royal Melbourne Hospital, Melbourne, Australia. , (Australia)
  • 4 Department of Urology, University of Minnesota, Minneapolis, MN, USA. [email protected]
  • 5 Urology Section 112D, Minneapolis VA Medical Center, One Veterans Drive, Minneapolis, MN, 55417, USA. [email protected]
Type
Published Article
Journal
World journal of urology
Publication Date
Nov 01, 2020
Volume
38
Issue
11
Pages
2981–2986
Identifiers
DOI: 10.1007/s00345-019-03032-x
PMID: 31784773
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To identify urologic systematic reviews (SRs) registered to PROSPERO that resulted in a publication, and to evaluate their methodological quality and concordance with their stated a priori protocols. We searched PubMed to identify urologic SR protocols registered in PROSPERO that resulted in a publication and assessed their methodological quality and protocols in relation to their stated a priori protocols in PROSPERO. Of the 576 urologic SR protocols registered in PROSPERO up to December 2017, 201 (34.9%) resulted in a full SR publication, but only 40 (17.7%) updated their registration record accordingly. Publications were spread over 100 different journals, with a median time-to-publication of 29 months (95% CI 25.0-33.0). The most common topic by far was prostate cancer (59.7%), followed by voiding issues (15.3%), and renal transplantation (15.3%). Only little over half the reviews (52.74%) explicitly stated primary outcome(s) that matched the primary outcome of their corresponding PROSPERO protocol. Notable methodologic deviations from registered protocols included planned restriction on study design (33%), heterogeneity analysis (42%) and planned risk of bias analysis (65.2%). SR authors in urology are increasingly using PROSPERO to register their titles, but our findings indicate that registration alone is not a guarantor of a high-quality SR product. There appears to be a critical need to raise the bar for review authors registering protocols in PROSPERO, with an emphasis on transparency in their publication status updates as well as deviations from their a priori protocols.

Report this publication

Statistics

Seen <100 times